GMPS — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21811226	1.00	3/20
SCHEMBL31237420	1.00	3/20
SCHEMBL21810993	1.00	2/20
SCHEMBL22971857	1.00	2/20
SCHEMBL24249569	0.91	2/20
SCHEMBL30865110	0.85	2/20
SCHEMBL24249552	0.81	2/20
SCHEMBL4354580	0.76	2/20
SCHEMBL4586985	0.73	2/20
SCHEMBL4585990	0.73	2/20
SCHEMBL8976404	0.66	2/20
Hydrochloric Acid (SCHEMBL8104687)	0.65	2/20
SCHEMBL19001586	0.64	2/20
SCHEMBL18996626	0.61	2/20
SCHEMBL28741151	0.61	2/20
SCHEMBL29639177	0.61	2/20
SCHEMBL8309178	0.61	2/20
SCHEMBL16363804	0.60	2/20
SCHEMBL4586103	0.57	2/20
SCHEMBL30946707	0.57	2/20

Clinical trials — most relevant to GMPS by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Switching of Sildenafil to Riociguat in CTEPH Patients	PHASE4	RECRUITING
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis	PHASE4	COMPLETED
Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis	PHASE4	RECRUITING
Vericiguat and Reverse Remodeling Indices in Heart Failure	PHASE4	RECRUITING
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
Chronic Sildenafil Treatment in Heart Failure	PHASE3	COMPLETED
Methylene Blue and Microcirculation in Septic Shock	PHASE3	UNKNOWN
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension	PHASE3	COMPLETED
Low Dose Versus High Dose Methylene Blue in Septic Patients	PHASE2/PHASE3	COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm	PHASE2	WITHDRAWN
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
A Study for Assessing the Efficacy and Safety of BH4 in Radiation Enteritis	PHASE2	UNKNOWN
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE	PHASE2	UNKNOWN
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease	PHASE2	COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm	PHASE1/PHASE2	COMPLETED
Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease	PHASE2	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers	PHASE1	COMPLETED
Effects of Carbon Monoxide Breathing on Blood Vessel Function	PHASE1	COMPLETED
Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL	EARLY_PHASE1	UNKNOWN
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors	nan	WITHDRAWN
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy	nan	WITHDRAWN
Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients	nan	WITHDRAWN
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
Arginine Metabolism in Youth With Type 2 Diabetes	nan	RECRUITING
Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis	nan	COMPLETED
Ccf mtDNA as a Neurodegenerative Biomarker	nan	UNKNOWN
Effects of Sildenafil in Resistant Hypertensives and Genetic Polymorphism	nan	COMPLETED
Endurance Performance at Altitude	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GMPS binder may also engage these)

Protein	Name	Similarity
Q3THK7	—	1.000	Q3THK7 →
Q4V7C6	—	1.000	Q4V7C6 →
Q5RA96	—	1.000	Q5RA96 →
Q9P772	—	0.994	Q9P772 →
C0R5H8	—	0.991	C0R5H8 →
Q09580	—	0.991	Q09580 →
Q2GHY2	—	0.990	Q2GHY2 →
Q89ZV6	—	0.990	Q89ZV6 →
Q6BLS3	—	0.990	Q6BLS3 →
Q46I26	—	0.990	Q46I26 →
A5ICM2	—	0.990	A5ICM2 →
Q7UFS3	—	0.990	Q7UFS3 →
A2BTY4	—	0.990	A2BTY4 →
O88428	—	0.990	O88428 →
Q3YT30	—	0.990	Q3YT30 →
CTPS2	CTP synthase 2	0.989	landscape →
Q5LGV6	—	0.989	Q5LGV6 →
A2BNG3	—	0.989	A2BNG3 →
Q8YT80	—	0.989	Q8YT80 →
Q756B7	—	0.989	Q756B7 →
Q7ZXP9	—	0.989	Q7ZXP9 →
A8G223	—	0.989	A8G223 →
P38625	—	0.989	P38625 →
Q5APF2	—	0.989	Q5APF2 →
Q6FUF3	—	0.989	Q6FUF3 →
Q3IHJ1	—	0.989	Q3IHJ1 →
B3H120	—	0.989	B3H120 →
A2BZD9	—	0.989	A2BZD9 →
A4G4U7	—	0.989	A4G4U7 →
Q3Z886	—	0.989	Q3Z886 →